You are here: Industry Insights > multiple myeloma

News List

FDA Approves isatuximab-irfc for Multiple Myeloma americanpharmaceuticalreview
March 04, 2020
The Food and Drug Administration (FDA) approved isatuximab-irfc (SARCLISA, Sanofi-Aventis) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma ...
I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China prnasia
January 05, 2020
I-Mab initiated two registrational trials with TJ202/MOR202 in relapsed or refractory MM in Taiwan, China in early 2019 and expanded these trials into mainland China in late 2019, after receiving IND clearance from the National Medical Products Administra
Frailty Score May Predict Outcomes in Multiple Myeloma drugs
January 02, 2020
A frailty scale that includes Eastern Cooperative Oncology Group performance status (ECOG PS) may predict outcomes for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) ...
DARZALEX Shows Overall Survival Benefit in Multiple Myeloma Patients americanpharmaceuticalreview
December 16, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 ALCYONE study, which showed the addition of DARZALEX® ...
Bluebird bio, Bristol-Myers’ multiple myeloma therapy shows promise in early study expresspharma
December 12, 2019
Bluebird bio Inc and Bristol-Myers Squibb Co recently reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
DARZALEX (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant firstwordpharma
December 10, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announcedoverall survival (OS) results from the Phase 3 ALCYONE study (Abstract #859) ...
FDA accepts BLA of Sanofi’s isatuximab in multiple myeloma pharmaceutical-technology
July 12, 2019
The US Food and Drug Administration (FDA) has agreed to review the biologics licence application (BLA) of Sanofi’s isatuximab to treat relapsed/refractory multiple myeloma (RRMM) patients.
NICE recommends Revlimid as multiple myeloma alternative pharmatimes
May 20, 2019
The National Institute of Health and Care Excellence (NICE) has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight blood cancer.
Celgene receives positive CHMP opinion for lenalidomide and pomalidomide for multiple myeloma patients biospectrumasia
April 02, 2019
The committee also recommended approval of IMNOVID in combination with bortezomib and dexamethasone (PVd)……
Venclexta safety warnings in multiple myeloma patients pharmatimes
March 27, 2019
The US Food and Drug Administration (FDA) has posted a safety statement to alert healthcare professionals and patients about the suspension of a clinical trial of bortezomib and low-dose dexamethasone with or without Venclexta (venetoclax).

Previous page 1 2 3 4 5 6 7 8 9 Next page